
























In late 90’s, the idea that manipulation of one single 
gene could significantly extend longevity of a complex 
model organism was certainly not an heretic one [1]. 
Successful attempts had already been made in worms 
and flies, not to speak about budding yeast, whose 
unicellular simplicity makes it somehow close to a cell 
culture system. It was already clear, in particular, that 
hypomorphic mutations in the insulin/Igf1 (IIS) 
pathway could enhance lifespan in Drosophila or C. 
Elegans, in a fashion that could mimic the effect of 
nutrient restriction, for the longest time the most 
reliable model for laboratory research on longevity.   
The role of insulin/Igf signaling in mediating body 
response to nutrients, and the fact that IIS is reduced by 
calorie restriction protocols, provided full rationale to 
these observations, that brought to the notion that aging 
may represent, rather than the uncontrolled catastrophe of 
the body, the product of a  genetically coded programme.  
Yet, report by Migliaccio and colleagues,  that mice 
lacking the 66kD isoform of the Shc (Src Homology and 
Collagen) protein family lived 30% longer than p66-
proficient littermates,  caught  the scientific community 
by surprise, especially because p66KO mice, not only 
were long lived, but appeared, unlike other murine 
models of longevity such as GH deficient dwarf mice, 
phenotypically normal, fertile and healthy [2].  
 
Shc proteins were known as adapter molecules, i.e. 
signaling components deputed to the assembly of  macro- 
 
 























molecular complexes downstream of activated growth 
factor receptors (RTKs). A role for SHCs in insulin 
signaling, in particular, had also been reported [3]. 
Thus, one could have easily welcomed the p66KO 
mouse as the first (or one of the first) mammalian 
example(s) of extended longevity by genetic attenuation 
of insulin/Igf signaling. Another one, the Igf-1 receptor 
(IGF-1R)  knock-out mouse, was going to come shortly 
after [4]. 
   
Instead, the linkage between p66 and longevity took an 
unexpected direction, becoming one of the strongest 
arguments in support of the Harman’s “free radical 
theory of aging” [5]: in fact, p66- deficient mice and 
cells were found to present remarkably reduced levels 
of ROS and increased resistance to oxidative stress.  
 
Attenuation of insulin signaling leads per se to reduced 
oxidative burden, by Daf-16/FoxO dependent up-
regulation of antioxidant defenses [6]; thus, the oxidant-
resistant phenotype of p66KO mice could still fit in the 
genetic model of longevity centered on the insulin/Igf 
signaling cascade. Instead, second surprise, solid 
biochemical studies revealed for p66shc a function 
completely distinct from that of the other SHC proteins: 
it was found that, in response to a number to pro-
oxidant and apoptogenic stimuli, p66shc translocates to 
mitochondria, where it directly generates reactive 
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its effect on longevity to ROS and mitochondria, in 
perfect agreement with Harman’s theories; accordingly, 
studies performed on p66KO mice involved p66 in a 
number of typical age-related diseases, including 
vascular diabetic complication and atherosclerosis, 
already suspected to be caused by excess oxidative 
stress [8].  Interestingly, in keeping with initial 
predictions, insulin signaling was indeed found to be 
defective in p66-deficient cells and mice, but that was 
again related to the molecule’s capacity to generate 
ROS, that facilitate tyrosine kinase signaling by 
transient and reversible inhibition of tyrosine 
phosphatases [9]. 
 
Accumulation of cellular and tissue oxidative damage, 
however, may nor represent the only, or even the most 
important, mechanism underlying body senescence and 
limitation of lifespan. Mounting evidence indicate that  
effects of calorie restriction on longevity involve a 
number of nutrient-sensing molecular networks that 
regulate, beside ROS generation and scavenging, also 
DNA repair, inflammation, cell proliferation and body 
growth (i.e. accumulation of  biomass) [10]. One of 
these evolutionarily conserved networks involves the 
sirtuin family of NAD+ dependent histone deacetylases 
(sirtuin 1 through 7 in mammals) that regulate 
chromatin remodelling and gene transcription in 
response to cellular energy status [11]. Another major 
nutrient-sensing pathway is centered on the TOR 
(Target of Rapamycin) kinase and its downstream 
cascade. In mammalian cells, m(ammalian)TOR 
regulates ribosomal protein synthesis, cell growth, cell 
cycle progression, autophagy and mitochondrial 
function in response to the availability of aminoacids 
and the intracellular levels of ATP. Additionally, 
mTOR is activated by growth factor receptors. 
Including, of course, the insulin receptor [12].  
 
Several lines of evidence indicate that nutrient and 
insulin-dependent regulation of TOR and its 
downstream cascade may play a central role in aging 
and in the nutritional control of lifespan. In yeast, flies 
and worms, hypomorphic mutations in this cascade 
extend longevity [10]. Even more interestingly, the 
mTOR inhibitor Rapamycin  extends lifespan in mice 
and prevents age-related diseases [13], and so does 
genetic deletion of the ribosomal S6 kinase (S6K), a 
major downstream effector of mTOR [14]. Thus, 
inactivation of the mTOR pathway mimics the 
beneficial effect of calorie restriction in rodents, clearly 
indicating that mTOR-dependent signaling contributes 
to longevity determination by nutrients in mammals. 
Again, inhibition of TOR may lead to increased 
antioxidant defenses, as observed in yeast and flies [15], 
but could also promote autophagy and reduce   
intracellular accumulation of pathologic proteins, that 
eventually leads to  Endoplasmic Reticulum (ER) stress 
and tissue aging [16]. Notably, accumulation of 
misfolded proteins underlies typical senescence-
associated pathologies like Alzheimer’s and vascular   
amyloidosis, while ER stress contributes to insulin 
resistance and Metabolic Syndrome, another age-
dependent disease [17].   
 
Is there a relationship between p66-dependent aging and 
the regulation of longevity by nutrients, through the   
mTOR/S6K cascade? Or, in other words, does the 
mTOR/S6K cascade contribute to p66 effects on mouse 
lifespan? Recent work performed in our laboratory tried 
to address this seemingly relevant  question [18]. 
 
We were initially interested in determining whether 
p66shc may have a role in insulin resistance, the 
signaling dysfunction underlying glucose intolerance 
and type 2 diabetes associated with overnutrition and 
overweight. The question was legitimated by increasing 
evidence of a role for reactive oxygen species in insulin 
desensitization [19], and by our previous observation of 
reduced liver steatosis, a major inducer of insulin-
resistance, in p66KO mice [20]. We indeed found that  
obese (LepOb, leptin deficient) mice devoid of  p66, 
although gaining nearly as much weight as their p66-
proficient littermates, remained remarkably responsive 
to insulin and were significantly protected from 
diabetes. Importantly, this finding correlated with 
reduced levels of phosphorylation of S6K in the adipose 
tissue; additionally, isolated adipocytes from p66KO 
obese mice displayed reduced S6K activity and 
preserved insulin responsiveness compared to p66 WT 
cells, and p66KO preadipocytes were resistant to the 
insulin-desensitizing effect of excess fatty acids in vitro.  
 
These findings fitted with the current model whereby 
excess nutrient (glucose and Free Fatty Acids) and 
chronic hyperinsulinemia downregulate insulin response 
in target tissues by hyperactivating S6K, that in turn 
leads to serine phosphorylation and proteasomal 
degradation of the major insulin transducer IRS-1 [21]. 
p66 would participate in this circuitry by somehow 
stimulating S6K. Accordingly, we showed that 
overexpression of p66shc in 3T3L1 adipocytes leads to 
hyperactivation of S6K and to hyperphosphorylation of 
IRS on serine residues. Further molecular dissection of 
these biochemical events also revealed that p66shc 
forms a complex with S6K 1 and IRS-1, thus facilitating 
the signal-inibitory interaction between the two 
molecules. To our surprise, these effects of p66 were 
largely independent from changes in the intracellular 
redox state, or from the redox properties of p66 itself, 
   
www.impactaging.com                   515                                          AGING,    August 2010, Vol.2 No.8but seemingly explainable by the “traditional” function 
of p66shc as an adapter protein. We concluded that 
p66shc, at least in adipocytes, promoted insulin and 
nutrient signaling to S6K, and, consequently, the feed-
back inhibitory action of S6K on IRS-1, leading to 
diabetes in overfed animals. 
 
While these findings have obvious relevance for the 
understanding of signal deregulation connecting obesity 
and overnutrition to diabetes, our observation may add a 
novel  perspective to the linkage between p66shc and 
lifespan determination.  
 
In fact, ablation of p66, by leading to reduced 
responsiveness  of S6K to nutrients, creates a 
Rapamycin-like (although presumably milder) signaling 







































least by preventing one major age-related disease, type 2 
diabetes. In simpler words, p66 ablation could mimc 
calorie restricttion. Notably type 2 diabetes recapitulates 
and accelerates many pathologic changes (in vasculature, 
kidneys, eyes, peripheral nerves) that are typical of 
senescence. These changes hit tissues that are largely 
insulin-independent for their energy metabolism, but that 
are exposed to elevated amount of insulin and glucose 
imposed by whole body insulin resistance. Interestingly, 
obese mice lacking p66 live significantly longer than 
their p66WT controls (although less than lean, WT mice) 
[17]. On the other hand, laboratory animals fed ad 
libitum frequently develop overweight and glucose 
intolerance with age, indicating that effects of p66shc 
observed in the context of genetic obesity and diabetes  
may also be relevant to the aging process of non overtly 
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the S6K-related mechanisms for lifespan extension may 
operate, in view of our findings, in p66KO mice. For 
instance, reduced protein translation may attenuate ER 
stress in critical tissues and reduce progression and 
severity of  age-related diseases due to accumulation of 
misfolded proteins. While this possibility deserves to be 
tested in appropriate model systems (such as mice prone 
to  Alzheimer’s disease crossed to p66KO mice), we 
have preliminary evidence that overexpression of 
p66shc in preadipocites and kidney cells increases ER 
stress in parallel with hyperactivation of S6K. 
  
Along similar lines, increased autophagy, due to S6K 
attenuation, may contribute to the long-lived phenotype 
of p66 deficient animals, another possibility to be 
verified.  
 
Finally, prevention of cancer contributes to lifespan 
extension by calorie restriction and S6K blockade. This 
may be true also in p66KO mice. Interestingly, in spite 
of p66shc operating in the p53-initiated apoptotic 
pathway [22], no increase in tumor incidence has been 
described in this mouse strain. Based on our prediction 
such incidence may even be lower than in wild type 
animals, due, at least in part, to reduced mTOR/S6K 
signaling in cancer cells. This is again a testable 
hypothesis.  
 
Can these views be reconciled with current, “ROS-
centric” model for lifespan limitation by p66 [23]? 
 
In principle, ROS can operate both upstream and   
downstream of  the TOR cascade. In one scenario, p66 
action on S6K may lead to increased mitochondrial 
metabolism and as a consequence to a rise of 
mitochondrial ROS [24], as observed in cells were 
p66shc is overexpressed [2]. In simple terms, 
mTOR/S6K may mediate, at least in part, the pro-
oxidant action of p66 (Figure 1B). 
 
More intriguingly, ROS may act upstream of the 
p66/S6K module, since p66shc not only generates ROS, 
but is also stimulated by oxidants [2]. For instance, in 
fibroblasts exposed to oxidative stress, PI3K/AkT 
activation by ROS is mediated, at least to some extent, 
by p66shc [25]; AkT can, in turn, activate mTOR.  ROS 
are also generated in mitochondria in response to energy 
substrates; these species may increase the phospho-
rylation/expression level of p66, thereby promoting  its 
(redox-independent) stimulatory action on  S6K.  This 
would represent  an intriguing alterantive route for 
nutrients to signal, via mitochondria, ROS and p66shc, 
to the mTOR/S6K cascade (Figure 1A).   Of note, 
phosphorylation of p66, a modification that correlates  
with its biological activity, was found to be increased in 
pre-adipocytes exposed to hyperglycemia or excess 
FFA, as if p66 were actually behaving  as a  sensor of 
nutrient abundance in these cellular contexts [17].   
 
In all the above scenarios, p66, S6K and ROS lie on the 
same nutrient sensitive pathway, mechanistically linked  
to aging and potentially targetable by calorie restriction 
(Figure 1 A and B).  
 
In conclusion, the observation that p66shc contributes to 
S6K activation in response to glucose, amino acids and 
insulin, supports the concept that aging and age-related 
diseases  are driven by TOR (not by ROS) and p66sch 
accelerates aging by activating TOR [26]; revealing the  
existence of a  novel nutrient-regulated pathway to 
senescence,  in which p66shc works as an adaptor (what 
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